临床合理用药杂志
臨床閤理用藥雜誌
림상합리용약잡지
CHINESE JOURNAL OF CLINICAL RATIONAL DRUG USE
2014年
33期
41-42
,共2页
李建军%司淑伟%李建平%高秀芳%郑广茂%胡子伟
李建軍%司淑偉%李建平%高秀芳%鄭廣茂%鬍子偉
리건군%사숙위%리건평%고수방%정엄무%호자위
结肠炎,溃疡性%氨水杨酸%布拉氏酵母菌散%治疗结果
結腸炎,潰瘍性%氨水楊痠%佈拉氏酵母菌散%治療結果
결장염,궤양성%안수양산%포랍씨효모균산%치료결과
Colitis,ulcerative%Mesalazine%Saccharomyces boulardii sachets%Treatment outcome
目的:探讨美沙拉秦灌肠液联合布拉氏酵母菌散治疗溃疡性结肠炎的临床效果。方法选择本院2013年7月—2014年4月收治的轻、中度活动性溃疡性结肠炎患者80例,随机分为治疗组和对照组,各40例。治疗组给予美沙拉秦灌肠液联合布拉氏酵母菌散治疗,对照组仅给予美沙拉秦灌肠液治疗。观察两组患者的临床效果及不良反应。结果治疗后,治疗组总有效率为97.5%(39/40),高于对照组的77.5%(31/40),差异有统计学意义(P<0.05)。两组患者的不良反应未通过特殊处理均自行缓解。结论美沙拉秦灌肠液联合布拉氏酵母菌散治疗溃疡性结肠炎疗效确切。
目的:探討美沙拉秦灌腸液聯閤佈拉氏酵母菌散治療潰瘍性結腸炎的臨床效果。方法選擇本院2013年7月—2014年4月收治的輕、中度活動性潰瘍性結腸炎患者80例,隨機分為治療組和對照組,各40例。治療組給予美沙拉秦灌腸液聯閤佈拉氏酵母菌散治療,對照組僅給予美沙拉秦灌腸液治療。觀察兩組患者的臨床效果及不良反應。結果治療後,治療組總有效率為97.5%(39/40),高于對照組的77.5%(31/40),差異有統計學意義(P<0.05)。兩組患者的不良反應未通過特殊處理均自行緩解。結論美沙拉秦灌腸液聯閤佈拉氏酵母菌散治療潰瘍性結腸炎療效確切。
목적:탐토미사랍진관장액연합포랍씨효모균산치료궤양성결장염적림상효과。방법선택본원2013년7월—2014년4월수치적경、중도활동성궤양성결장염환자80례,수궤분위치료조화대조조,각40례。치료조급여미사랍진관장액연합포랍씨효모균산치료,대조조부급여미사랍진관장액치료。관찰량조환자적림상효과급불량반응。결과치료후,치료조총유효솔위97.5%(39/40),고우대조조적77.5%(31/40),차이유통계학의의(P<0.05)。량조환자적불량반응미통과특수처리균자행완해。결론미사랍진관장액연합포랍씨효모균산치료궤양성결장염료효학절。
Objective To investigate the clinical efficacy of mesalazine enema liquid and saccharomyces boulardii sa-chet treating ulcerative colitis. Methods 80 patients with mild-moderate ulcerative colitis in our hospital from July 2013 to A-pril 2014,were randomly divided into treatment group(n=40)and the control group(n=40). The treatment group was trea-ted with mesalazine enema liquid and saccharomyces boulardii sachet,while the control group was treated with mesalazine enema liquid. The clinical effect and adverse reaction of two groups were compared. Results After treatment,the effective rate of treatment group was 97. 5%(39/40),which was higher than that of control group of 77. 5%(31/40),the difference was sta-tistically significant( P<0. 05). Adverse reactions of the two groups were relieved itself without special treatment. Conclusion The effect of mesalazine enema liquid and saccharomyces boulardii sachet in treating ulcerative colitis is remarkable.